Is “15% of the scale range” Universally Applicable to Define “MID” and Clinical Relevance of Patient-Reported Treatment Benefits? Group Discussion with the ISPOR Clinical Outcome Assessment Special Interest Group
Speakers: Olivier Chassany, MD, PhD, Health Economics Clinical Trial Unit,, Greater Paris University Hospitals (AP-HP), Paris, 75, France James W Shaw, PhD, PharmD, MPH, Bristol-Myers Squibb, Doylestown, PA, USA; Katja Rudell, PhD, MSc, Parexel Access Consulting, Parexel International, Chittering, UK
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG) updated its general methods on benefit assessment. An important recommendation, within this update, was the inclusion of considering the score scale range of an instrument when defining a responder threshold to designate important individual-level changes. Specifically, the threshold should be at least 15% of the scale range. The ISPOR Clinical Outcome Special Interest Group will host a group discussion to debate the implications of such a recommendation. There will be a focused discussion on the pros and cons of this across-the-board approach, including considerations of patient input into meaningful change, therapeutic areas and target populations, available effective treatments, and psychometric aspects.
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada